Study Finds Cancer Metabolite Modifies Key Proteins

Researchers identify a new lysine modification triggered by the oncometabolite R2HG, which can suppress immune cell development.

Updated on Nov. 18, 2026 in Cancer

Bold flat-color editorial illustration showing a chain of geometric blocks in deep red and cream, with one block altered by a stacked-cube protrusion, evoking a molecular modification.
Researchers report that the cancer-linked metabolite R2HG chemically modifies the enzyme GSTP1 at lysine 209, dramatically suppressing monocyte differentiation in lab tests. AI Illustration. Upload story photo >

Researchers designed R2HG-mimicking probes and identified lysine-R2HGylation as a post-translational modification in cancers with elevated R2HG. The work was published as an accepted article on nature.com.

Why it matters

R2HG is produced mainly by mutated IDH1/2 enzymes found in a range of cancers, and the findings suggest it can contribute to cancer development by chemically altering biologically critical lysine residues. Understanding this mechanism may help clarify how these tumors affect cell behavior.

The evidence comes from laboratory experiments using R2HG-mimicking probes, which identified the C5-linked modification on GSTP1 at lysine 209 and showed SIRT5 acts as a deacylase for it in vitro. Whether these effects occur in vivo or in human tumors remains unresolved.

The players

SIRT5

SIRT5 is a mitochondrial sirtuin enzyme that removes acyl groups from lysine residues on target proteins, and in this study it acted as a deacylase for the GSTP1 modification.

GSTP1

GSTP1 is a glutathione S-transferase enzyme involved in detoxification and cellular redox regulation, and in this study its activity was inhibited by the R2HG-linked lysine modification.

The details

Researchers used R2HG-mimicking probes to map lysine-R2HGylation sites and confirmed the modification on GSTP1 at lysine 209. The team found R2HG slightly but significantly inhibits GSTP1 activity through this modification and dramatically suppresses monocyte differentiation.

Timeline

  1. Accepted article published early on nature.com on November 18, 2026.

Big Picture

The work extends the research line that identified 2-hydroxyglutarate as an oncometabolite made by mutant IDH1/2 enzymes, adding a direct protein-modification mechanism to the metabolic effects previously described. It suggests oncometabolites may act through chemical changes to proteins as well as through enzyme inhibition.

For now this work is laboratory research and does not change how cancer is diagnosed or treated. Readers should view it as early mechanistic science that may inform future drug development rather than as a direct treatment advance.

The takeaway

Laboratory findings on how cancer-linked metabolites alter proteins can clarify tumor biology, but they typically take years of further testing before affecting patient care. Readers should treat such results as early-stage science.

Further reading

Explore more research on Cancer to see how metabolic changes in tumors are being studied.

Source note: This article includes information reported by Nature.